Michael Fehlings
Impact in
- Oncology top 2%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immunology top 2%
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- IL-33, ST2, and ILC Pathways
- Immune cells in cancer
Papers in
- Immunology 12
- T-cell and B-cell Immunology 6
- IL-33, ST2, and ILC Pathways 3
- Immunotherapy and Immune Responses 3
- Immune cells in cancer 2
- Oncology 13
- Cancer Immunotherapy and Biomarkers 12
- Co-authors
- Evan William Newell (11 shared papers)Alessandra Nardin (9 shared papers)Takuro Noguchi (2 shared papers)Ekaterina Esaulova (2 shared papers)Stephen T. Oh (2 shared papers)Cora D. Arthur (2 shared papers)Catrina C. Fronick (2 shared papers)Jeffrey P. Ward (2 shared papers)
- Journals
- Journal for ImmunoTherapy of Cancer (4 papers)Immunity (3 papers)Journal of Clinical Investigation (2 papers)Cell (2 papers)Nature Communications (1 paper)
- Partner nations
- United StatesSingaporeUnited Kingdom
In The Last Decade
Michael Fehlings
29 papers receiving 2.9k citations
Michael Fehlings's Hit Papers
Peers
Comparison fields: 5 of 78
- Oncology 1.3k
- Immunology 1.1k
- Infectious Diseases 383
- Physiology 53
- Hepatology 74
Countries citing papers authored by Michael Fehlings
This map shows the geographic impact of Michael Fehlings's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Fehlings with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Fehlings more than expected).
Fields of papers citing papers by Michael Fehlings
This network shows the impact of papers produced by Michael Fehlings. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Fehlings. The network helps show where Michael Fehlings may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael Fehlings, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 31 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates Hit paper breakdown → | 2018 | 1091 |
| 2 | 2016 | 380 | |
| 3 | 2018 | 354 | |
| 4 | 2021 | 195 | |
| 5 | 2020 | 150 | |
| 6 | 2021 | 82 | |
| 7 | 2021 | 77 | |
| 8 | 2018 | 76 | |
| 9 | 2018 | 76 | |
| 10 | 2019 | 75 | |
| 11 | 2022 | 75 | |
| 12 | 2019 | 58 | |
| 13 | 2022 | 56 | |
| 14 | 2022 | 39 | |
| 15 | 2018 | 28 | |
| 16 | 2023 | 23 | |
| 17 | 2023 | 19 | |
| 18 | 2017 | 11 | |
| 19 | 2024 | 11 | |
| 20 | 2020 | 10 |
About Michael Fehlings
Michael Fehlings is a scholar working on Immunology, Oncology, Infectious Diseases, Molecular Biology and Virology, having authored 31 papers that have together received 2.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (12 papers), T-cell and B-cell Immunology (6 papers), SARS-CoV-2 and COVID-19 Research (5 papers), vaccines and immunoinformatics approaches (3 papers), IL-33, ST2, and ILC Pathways (3 papers), Immunotherapy and Immune Responses (3 papers), Immune cells in cancer (2 papers) and HIV Research and Treatment (1 paper). The work is most often cited by research in Oncology (1.3k citations), Immunology (1.1k citations), Infectious Diseases (383 citations), Physiology (53 citations) and Hepatology (74 citations). Michael Fehlings has collaborated with scholars based in United States, Singapore and United Kingdom. Frequent co-authors include Evan William Newell, Alessandra Nardin, Takuro Noguchi, Ekaterina Esaulova, Stephen T. Oh, Cora D. Arthur, Catrina C. Fronick, Jeffrey P. Ward, Daniele Runci and Matthew M. Gubin. Their work appears in journals such as Journal for ImmunoTherapy of Cancer, Immunity, Journal of Clinical Investigation, Cell and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.